Label-Free Quantitative Proteomics and Substrate-Based Mass Spectrometry Imaging of Xenobiotic Metabolizing Enzymes in Ex Vivo Human Skin and a Human Living Skin Equivalent Model
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 49 (1) , 39-52
Abstract
We report for the first time label-free quantification of xenobiotic metabolizing enzymes (XME), transporters, redox enzymes, proteases and nucleases in six human skin explants and a 3D living skin equivalent model from LabSkin. We aimed to evaluate the suitability of LabSkin as an alternative to animal testing for the development of topical formulations. More than 2000 proteins were identified and quantified from total cellular protein. Alcohol dehydrogenase 1C (ADH1C), the most abundant phase I XME in human skin, and glutathione S-transferase pi 1 (GSTP1), the most abundant phase II XME in human skin, were present in similar abundance in LabSkin. Several esterases were quantified and esterase activity was confirmed in LabSkin using substrate-based mass spectrometry imaging. No cytochrome P450 (CYP) activity was observed for the substrates tested, in agreement with the proteomics data, where the cognate CYPs were absent in both human skin and LabSkin. Label-free protein quantification allowed insights into other related processes such as redox homeostasis and proteolysis. For example, the most abundant antioxidant enzymes were thioredoxin (TXN) and peroxiredoxin-1 (PRDX1). This systematic determination of functional equivalence between human skin and LabSkin is a key step towards the construction of a representative human in vitro skin model, which can be used as an alternative to current animal-based tests for chemical safety and for predicting dosage of topically administered drugs. Significance Statement The use of label-free quantitative mass spectrometry to elucidate the abundance of xenobiotic metabolizing enzymes, transporters, redox enzymes, proteases and nucleases in human skin enhance our understanding of the skin physiology and biotransformation of topical drugs and cosmetics. This will help develop mathematical models to predict drug metabolism in human skin and to develop more robust in vitro engineered human skin tissue as alternatives to animal testing.Keywords
This publication has 45 references indexed in Scilit:
- Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small IntestineDrug Metabolism and Disposition, 2020
- Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global ProteomicsMolecular Pharmaceutics, 2019
- Identification and quantification of blood–brain barrier transporters in isolated rat brain microvesselsJournal of Neurochemistry, 2018
- The role of glutathione reductase and related enzymes on cellular redox homoeostasis networkFree Radical Biology and Medicine, 2016
- Skin Redox Balance Maintenance: The Need for an Nrf2-Activator Delivery SystemCosmetics, 2016
- The development of a 3D immunocompetent model of human skinBiofabrication, 2013
- Partition and Turnover of Glutathione Reductase from Saccharomyces cerevisiae: A Proteomic ApproachJournal of Proteome Research, 2013
- Development of a 3D human in vitro skin co‐culture model for detecting irritants in real‐timeBiotechnology and Bioengineering, 2010
- Cytochrome P450: A Target for Drug Development for Skin DiseasesJournal of Investigative Dermatology, 2004
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976